Placebo-controlled, randomized trial to evaluate the intestinal environments by the continuous supplementation of apple polyphenols - Evaluation of the intestinal environments by the continuous supplementation of apple polyphenols

Food Research Institute, National Agriculture and Food Research Organization0 个研究点目标入组 68 人开始时间: 2024年3月31日最近更新: 2024年9月2日

试验速览

阶段: Unknown
状态: 已完成
发起方
入组人数: 68

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 40years-old 至 65years-old（—）
性别: All

入选标准

未提供

排除标准

•(1)Those who regularly take supplements that contain ingredients that may affect the results of this study (2) Those who are participating in other clinical trials at the start of this study (3) Who have ever complained of physical discomfort due to ingestion of apples or polyphenols (4) Patients with a history of heart failure or myocardial infarction (5) Excluded due to diseases (6) Those suffering from serious cerebrovascular disease, cardiac disease, liver disease, renal disease, gastrointestinal disease, or infectious disease requiring notification. (7) Those who have a history of major surgery on the digestive system, such as gastrectomy, gastrointestinal suture, or intestinal resection (8) Those with significant abnormalities in physical measurements, blood pressure measurements, or blood tests (9) Those with a low hemoglobin level (10) Women around menopause who show significant changes in their physical condition (11) Persons who may show allergic symptoms to drugs or foods (12) Excessive smokers: smokers who generally smoke 21 or more cigarettes per day (13) Regular users of alcohol: Those who generally drink more than 20 g of pure alcohol per day (14) Those whose lifestyle is extremely irregular: frequently skip two or more meals, eat out for dinner almost every day, work night shifts, or do not regularly take days off (15) Women who have donated 400 mL blood within 16 weeks prior to the start of intake, men who have donated 400 mL blood within 12 weeks prior to the start of intake, and those who have donated 200 mL blood within 4 weeks or component blood within 2 weeks prior to the start of intake (16) Women who are pregnant or possibly pregnant, or lactating (17) Any participant in any other clinical trial, observational study, clinical trial, or home use test between 4 weeks prior to the start of the study period and the end of the intake period (18) Any other person deemed ineligible by the principal investigator

研究者

发起方

Food Research Institute, National Agriculture and Food Research Organization

相似试验

招募中

4 期

Role of repetitive transcranial magnetic stimulation (rTMS) in migraine prophylaxis a randomized control trial

CTRI/2012/04/002545Sanjay Gandhi Postgraduate Institute of Medical Sciences100

已完成

不适用

A randomised placebo controlled trial to examine the effect and onset of action of dutasteride on the expression of vascular endothelial growth factor and microvessel densitySurgery: ProstatectomySurgery

ISRCTN18102429Department of Health

进行中（未招募）

不适用

Placebo-controlled Randomized Trial to evaluate the Effect of Elafin on Cytokine Profiles after Major Surgery - Phase II - ElafiEsophagectomy is the surgical removal of all or part of the esophagus. The patients enrolled in the study will undergo this surgery for treatment of esophageal cancer. The condition under investigation is the postoperative inflammatory syndrome (SIRS) after esophagectomy.

EUCTR2008-000938-49-DEProteo Biotech AG

进行中（未招募）

1 期

A study to examine the safety, tolerability and effects on abnormal bone formation of REGN2477 in patients with Fibrodysplasia Ossificans ProgressivaFibrodysplasia Ossificans Progressiva (FOP)MedDRA version: 20.0Level: PTClassification code 10068715Term: Fibrodysplasia ossificans progressivaSystem Organ Class: 10010331 - Congenital, familial and genetic disorders

EUCTR2016-005035-33-ITREGENERON PHARMACEUTICALS, INC.44

进行中（未招募）

1 期

EUCTR2016-005035-33-GBRegeneron Pharmaceuticals, Inc.40